Skip to main content

Market Overview

Dare Bioscience: Q4 Earnings Insights

Share:

 

Shares of Dare Bioscience (NASDAQ:DARE) decreased 2.4% in pre-market trading after the company reported Q4 results.

Quarterly Results

Earnings per share fell 4.76% year over year to ($0.22), which missed the estimate of ($0.13).

Revenue of $0 unchanged by 0.00% year over year, which missed the estimate of $520,000.

Guidance

Dare Bioscience hasn't issued any earnings guidance for the time being.

Revenue guidance hasn't been issued by the company for now.

How To Listen To The Conference Call

Date: Mar 30, 2021

Time: 04:30 PM

ET Webcast URL: https://edge.media-server.com/mmc/p/8uh76a7g

Recent Stock Performance

52-week high: $3.85

52-week low: $0.82

Price action over last quarter: Up 49.09%

Company Profile

Dare Bioscience Inc is a clinical-stage biopharmaceutical company focused on women's reproductive health. The products of the company are related to fertility, vaginal health, and contraception. Ovaprene is a product designed by the company to provide multiple weeks of contraceptive protection without the use of hormones.

 

Related Articles (DARE)

View Comments and Join the Discussion!

Posted-In: BZI-RecapsEarnings News

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com